Provided by Tiger Trade Technology Pte. Ltd.

ADC Therapeutics SA

4.01
+0.10002.56%
Post-market: 4.010.00000.00%19:23 EST
Volume:1.05M
Turnover:4.25M
Market Cap:496.75M
PE:-2.78
High:4.20
Open:3.97
Low:3.93
Close:3.91
52wk High:4.80
52wk Low:1.05
Shares:123.88M
Float Shares:92.24M
Volume Ratio:1.46
T/O Rate:1.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4417
EPS(LYR):-1.6246
ROE:-705.53%
ROA:-23.98%
PB:-2.09
PE(LYR):-2.47

Loading ...

ADC Therapeutics Grants Stock Options to New Employees Under Inducement Plan

Reuters
·
Feb 03

RBC Capital Sticks to Their Buy Rating for ADC Therapeutics (ADCT)

TIPRANKS
·
Jan 23

ADC Therapeutics Projects Cash Runway Through 2028 with 2025 Revenue at $73 Million

Reuters
·
Jan 09

ADC Therapeutics Grants Stock Options to New Employee

Reuters
·
Jan 03

ADC Therapeutics Sa - Selling Shareholders May Offer 14,696,253 Common Shares From Time to Time- SEC Filing

THOMSON REUTERS
·
Dec 13, 2025

ADC Therapeutics Reports 89.8% Response Rate in ZYNLONTA and Glofitamab Phase 1b Trial for r/r DLBCL

Reuters
·
Dec 06, 2025

Why Is ADC Therapeutics Plunging Today

Benzinga_recent_news
·
Dec 04, 2025

Crude Oil Gains 1%; Macy's Reports Strong Q3 Results

Benzinga
·
Dec 04, 2025

ADC Therapeutics Down Nearly 30%, on Pace for Largest Percent Decrease in Almost a Year -- Data Talk

Dow Jones
·
Dec 04, 2025

ADC Therapeutics Shares Fall After Two Deaths in Trial for Blood Cancer Treatment

Dow Jones
·
Dec 03, 2025

ADC Therapeutics Says Updated Data for Drug Supports Potential Best-in-Class Regimen in Lymphoma Patients

MT Newswires Live
·
Dec 03, 2025

ADC Therapeutics Sa - Lotis-7 Trial on Track for Complete Enrollment in 1H 2026

THOMSON REUTERS
·
Dec 03, 2025

ADC Therapeutics Announces Updated Data From Lotis-7 Phase 1B Clinical Trial of Zynlonta® in Combination With Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

THOMSON REUTERS
·
Dec 03, 2025

ADC Therapeutics Announces LOTIS-7 Trial Update on ZYNLONTA Combination in Relapsed DLBCL

Reuters
·
Dec 03, 2025

ADC Therapeutics to Provide Update on Lotis-7 Clinical Trial

THOMSON REUTERS
·
Dec 03, 2025

ADC Therapeutics files to sell 14.7M common shares for holders

TIPRANKS
·
Nov 11, 2025

BRIEF-ADC Therapeutics SA - Selling Shareholders May Offer 14.7 Million Common Shares - SEC Filing

Reuters
·
Nov 11, 2025

ADC Therapeutics Sa - Selling Shareholders May Offer 14.7 Mln Common Shares - SEC Filing

THOMSON REUTERS
·
Nov 11, 2025

ADC Therapeutics FY2025 Q3 Earnings Call Summary and Q&A Highlights: Clinical Progress and Strategic Financial Moves

Earnings Call
·
Nov 10, 2025

ADC Therapeutics (ADCT) Earnings Call Transcript

Motley Fool Transcribing
·
Nov 10, 2025